---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030435"
form_type: "8-K"
ticker: "ALBT"
cik: "0001630212"
company_name: "Avalon GloboCare Corp."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:16:59.846441+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalon GloboCare granted Chinese patent for CAR-T/NK cell technology; term 20 years

## Summary
- Patent CN 114502188 B issued by CNIPA, effective April 4, 2025, with 20-year protection.
- Co-developed with Hong Kong-based Arbele Limited; covers bispecific anti-CD19xCD22 CAR and localized cytokine induction.
- Enhances expansion, manufacturing, survival, and efficacy of CAR-T and CAR-NK cells.
- Adds to existing U.S. and PCT protections, strengthening global IP portfolio for cell-based immunotherapy.

## SEC filing metadata
- accession: 0001213900-25-030435
- form_type: 8-K
- ticker: ALBT
- cik: 0001630212
- company_name: Avalon GloboCare Corp.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630212/000121390025030435/0001213900-25-030435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630212/000121390025030435/ea0237706-8k_avalon.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030435
- JSON: https://secwatch.observer/filing/0001213900-25-030435.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.